A Randomized, Open-label, Multicentric Phase II Trial of PEMBROLIZUMAB (Keytruda®) With Chemotherapy Versus Chemotherapy Alone (Standard of Care) as Neo Adjuvant Treatment of Ovarian Cancer Not Amenable to Front Line Debulking Surgery.
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms NEOPEMBROV
- Sponsors ARCAGY/GINECO Group
- 31 Aug 2018 Biomarkers information updated
- 09 Jan 2018 Planned initiation date changed from 1 Sep 2017 to 1 Feb 2018.
- 11 Sep 2017 New trial record